N-[(1R)-1-phenylethyl]ethenesulfonamide | 1216845-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(1R)-1-phenylethyl]ethenesulfonamide
• CAS: 1216845-12-3
• 化学式: C₁₀H₁₃NO₂S
• 分子量: 211.285
• InChiKey: PXZOXOJEZLNUFJ-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[(1R)-1-phenylethyl]ethenesulfonamide 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 (8R,9aS)-8-hydroxy-2-((R)-1-phenylethyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide
  参考文献：
  名称：

  Rapid, Scalable Assembly of Stereochemically Rich, Mono- and Bicyclic Acyl Sultams

  摘要：

  A one-pot, sequential protocol is reported that involves complementary ambiphile pairing (CAP) of a vinyl sulfonamide with a variety of unprotected amino acids via aza-Michael addition and subsequent intramolecular amidation. The method generates diverse, sp(3)-rich mono- and bicyclic acyl sultams in a highly scalable manner. Modular pairing of stereochemically rich building blocks allows quick access to all possible isomers. Extension to include one-pot, sequential 3-, 4-, and 5-multicomponent protocols is also discussed.

  DOI：

  10.1021/ol403070w
• 作为产物：
  描述：

  2-氯乙烷磺酰氯 、 R(+)-alpha-甲基苄胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 生成 N-[(1R)-1-phenylethyl]ethenesulfonamide
  参考文献：
  名称：

  Rapid, Scalable Assembly of Stereochemically Rich, Mono- and Bicyclic Acyl Sultams

  摘要：

  A one-pot, sequential protocol is reported that involves complementary ambiphile pairing (CAP) of a vinyl sulfonamide with a variety of unprotected amino acids via aza-Michael addition and subsequent intramolecular amidation. The method generates diverse, sp(3)-rich mono- and bicyclic acyl sultams in a highly scalable manner. Modular pairing of stereochemically rich building blocks allows quick access to all possible isomers. Extension to include one-pot, sequential 3-, 4-, and 5-multicomponent protocols is also discussed.

  DOI：

  10.1021/ol403070w

文献信息

• Orally Bioavailable Caffeic Acid Related Anticancer Drugs
  申请人：Priebe Waldemar

  公开号：US20070232668A1

  公开（公告）日：2007-10-04

  The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.

  本发明涉及化合物及其用于治疗细胞增殖性疾病如癌症的用途。本发明的化合物作为Jak2/STAT3途径和下游靶点的抑制剂显示出显著的效力，并抑制癌细胞系的生长和存活。
• ORALLY BIOAVAILABLE CAFFEIC ACID RELATED ANTICANCER DRUGS
  申请人：The Board of Regents of the University of Texas System

  公开号：US20150094343A1

  公开（公告）日：2015-04-02

  The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.

  本发明涉及化合物及其用于治疗细胞增殖性疾病，例如癌症。本发明的化合物作为Jak2 / STAT3途径及下游靶点的抑制剂具有显著的效力，并抑制癌细胞系的生长和存活。
• 10.1021/0l100035e
  作者：Rolfe, Alan、Samarakoon, Thiwanka B.、Hanson, Paul R.

  DOI：10.1021/0l100035e

  日期：——
• US8779151B2
  申请人：——

  公开号：US8779151B2

  公开（公告）日：2014-07-15
• [EN] ORALLY BIOAVAILABLE CAFFEIC ACID RELATED ANTICANCER DRUGS<br/>[FR] MÉDICAMENTS ANTICANCÉREUX BIODISPONIBLES PAR VOIE ORALE ASSOCIÉS À L'ACIDE CAFÉIQUE
  申请人：UNIV TEXAS

  公开号：WO2007115269A2

  公开（公告）日：2007-10-11

  [EN] The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.
  [FR] La présente invention concerne des composés et leur utilisation pour traiter des maladies de prolifération cellulaire telles que le cancer. Les composés de la présente invention affichent une activité importante comme inhibiteurs des voies Jak2/STAT3 et des cibles en aval et inhibent la croissance et la survie des lignées de cellules cancéreuses.